SCYNEXIS, Inc.
NASDAQ: SCYX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- David Angulo
- Employees
- 18
- Headquarters
- Jersey City, United States
- IPO year
- 2014
- Market cap
- $24.3M
- Website
- https://www.scynexis.com
Loading SCYX…
Loading profile data…Frequently asked questions about SCYX
What does SCYNEXIS, Inc. (SCYX) do?
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber,...
Where does SCYX trade?
SCYNEXIS, Inc. (SCYX) trades on the NASDAQ.
What sector is SCYX in?
SCYNEXIS, Inc. (SCYX) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of SCYNEXIS, Inc.?
David Angulo is the chief executive officer of SCYNEXIS, Inc. (SCYX).
Where is SCYNEXIS, Inc. headquartered?
SCYNEXIS, Inc. is headquartered in United States.
Does SCYX pay a dividend?
SCYNEXIS, Inc. (SCYX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SCYX go public?
SCYNEXIS, Inc. (SCYX) completed its initial public offering in 2014.